. A set-point model with oscillatory behavior predicts the time course of 8-OH-DPATinduced hypothermia. Am J Physiol Regulatory Integrative Comp Physiol 281: R2059-R2071, 2001.-Agonists for the 5-hydroxytryptamine (HT)1A receptor induce a hypothermic response that is believed to occur by lowering of the body's set-point temperature. We have developed a physiological model that can be used to predict the complex time course of the hypothermic response after administration of 5-HT 1A agonists to rats. In the model, 5-HT1A agonists exert their effect by changing heat loss through a control mechanism with a thermostat signal that is proportional to the difference between measured and set-point temperature. Agonists exert their effect in a direct concentration-dependent manner, with saturation occurring at higher concentrations. On the basis of simulations, it is shown that, depending on the concentration and the intrinsic efficacy of a 5-HT 1A agonist, the model shows oscillatory behavior. The model was successfully applied to characterize the complex hypothermic response profiles after administration of the reference 5-HT 1A agonists R-8-hydroxy-2-(di-n-propylamino)tetralin (R-8-OH-DPAT) and S-8-OH-DPAT. This analysis revealed that the observed difference in effect vs. time profile for these two reference agonists could be explained by a difference in in vivo intrinsic efficacy.
pharmacokinetic-pharmacodynamic modeling; 5-hydroxytryptamine 1A receptor; R-8-hydroxy-2-(di-n-propylamino)tetralin; S-8-hydroxy-2-(di-n-propylamino)tetralin
IT IS WELL ESTABLISHED that the 5-hydroxytryptamine (HT) 1A receptor plays a role in the physiological regulation of body temperature (40, 54) . Consequently, the 5-HT 1A agonists, which are used therapeutically as antidepressants and antianxiety drugs (16) , cause hypothermia (4, 20, 27, 50) . For the prototype 5-HT 1A agonists it has been demonstrated that this hypothermic response is indeed mediated specifically through the 5-HT 1A receptor because it can be blocked in a dose-dependent manner by the selective, competitive 5-HT 1A receptor antagonist WAY-100,635 (14, 17) and not by antagonists for other G protein-coupled receptors (34) .
In a number of investigations, the time course of the hypothermic response after administration of 5-HT 1A receptor agonists has been studied in detail. In these studies, complex effect vs. time patterns have been observed, suggesting the involvement of homeostatic control mechanisms (51, 54) . So far, however, no mathematical models have been developed to characterize these complex time profiles of the hypothermic response in a strict quantitative manner. Specifically, there have been no attempts to link existing temperature regulation models (25, 49) to pharmacokinetic models describing the time course of the drug concentration in the body.
In recent years important progress has been made in the area of integrated pharmacokinetic-pharmacodynamic (PK-PD) modeling (11) . PK-PD modeling has even allowed estimation of the in vivo affinity and intrinsic efficacy of drugs (43) (44) (45) (46) . Specifically, models have been proposed that allow for a delay between drug concentration and the pharmacological response (15, 19, 30) . So far, however, very few of these models incorporate complex regulatory behavior (7, 18, 48) . In this report we propose a new physiological PK-PD model, in which 5-HT 1A receptor agonists exert their effect on body temperature by lowering of the set-point temperature. The model was applied to characterize hypothermic response vs. time profiles after administration of different doses of the reference 5-HT 1A receptor agonists R-and S-8-OH-DPAT. It is shown that differences in the observed hypothermic response profiles can be explained by differences in in vivo intrinsic efficacy between the two compounds.
Glossary a
Rate of change in the set-point signal (min Ϫ1 ⅐°C Ϫ1 ) AIC Akaike Information Criterion C Drug concentration in the central compartment (ng/ml) CL Clearance of the drug from the body (ml/min) CL 2, CL3
Intercompartmental clearance (ml/min) ε Residual error Interindividual variation ␥ Amplification of the set-point signal I
Identity matrix k in Zeroth-order rate constant associated with the production of body heat (°C/min) k out First-order rate constant associated with the cooling of the body (min Ϫ1 ) Eigenvalue M Jacobian matrix n Slope factor P Population parameter P i
Individual's parameter 50 Concentration at 50% of maximum stimulation S max
R-7-OH-DPAT R-(ϩ)-7-hydroxy-2-(di-n-propylamino) tetralin R-8-OH-DPAT R-(ϩ)-8-hydroxy-
Maximum stimulation the drug can produce T Core body temperature (°C) Fixed effect T min Population-averaged minimal temperature (°C) T SP Individual's set-point temperature (°C) V 1 Volume of distribution of the central compartment (ml) V 2, V3
Volume of distribution of the peripheral compartments (ml) WAY-100,635
SET-POINT MODEL FOR 5-HT1A AGONIST-INDUCED HYPOTHERMIA
The proposed set-point model for the effect of 5-HT 1A agonists on body temperature is shown in Fig. 1 . As the agonist binds to its receptor, a stimulus is generated. This stimulus in turn drives physiological processes that lower the temperature. This stimulus, which is determined by the drug-receptor interaction and hence the drug's affinity and efficacy, can be described by a sigmoidal function f(C)
where S max represents the maximum stimulus the drug can produce, C is the drug concentration, SC 50 is the concentration required to produce 50% of the maximum stimulus, and n is a slope factor, which determines the steepness of the curve. As the drug concentration changes with time, the stimulus changes as well. As the stimulus S is assumed to be inhibitory, it is defined as S ϭ 1 Ϫ f(C). The behavior of the concentration C and the corresponding stimulus S is shown in Fig. 2, A and B. This stimulus induces the hypothermic response. The changing drug concentrations therefore govern the first time scale of the model. The second time scale on which the model operates is governed by physiological principles. The model that describes the hypothermic response utilizes the concepts of the indirect physiological response model as proposed by Dayneka et al. (15) and Gabrielsson et al. (19) . In this model the change in temperature (T) is described as an indirect response to either the inhibition of the production of body heat or the stimulation of its loss (Eq. 2)
Here k in represents the zeroth-order rate constant associated with the warming of the body and k out represents a first-order rate constant associated with the cooling of the body.
The indirect physiological response model is combined with the thermostat-like regulation of body temperature. This regulation is implemented as a continuous process in which the body temperature is compared with a reference or set-point temperature (T SP ) (Fig. 1) . It is accepted that 5-HT 1A agonists elicit hypothermia by decreasing the value of T SP , and hence T SP depends on the drug concentration C: T SP ϭ T SP (C). It is assumed that T SP is controlled by the drug concentration C through Eq. 3
where T 0 is the set-point value in the absence of any drug: T 0 ϭ T SP (0). Combining the indirect physiological (15) and takes into account rate constants associated with the warming of the body (kin) and cooling of the body (kout). The indirect physiological response model is combined with the thermostat-like regulation of body temperature, in which body temperature (T) is compared with a fixed reference or set-point temperature (TSP) at rate a, generating a set-point signal X. The extent to which the set-point value decreases is a function of drug concentration f(C), which decreases X by the amplification factor ␥.
response model with the thermostat-like regulation therefore yields
in which X denotes the thermostat signal. In the model as described in Eq. 4, the change in X is driven by the difference between the body temperature T and T SP on a time scale that is governed by a. Hence, when the set-point value is lowered, the body temperature is perceived as too high and X is lowered. To relate this decreasing signal to the drop in body temperature, an effector function X Ϫ␥ was designed, in which ␥ determines the amplification. Raising this function to the loss term k out ⅐ T therefore facilitates the loss of heat. In Eq. 4, body temperature and set-point temperature are interdependent, and a feedback loop is created that can give rise to oscillatory behavior, as will be shown later. When the body temperature is at its initial set point, the no-drug situation, the equilibrium set-point signal X 0 can be defined in terms of k in , k out , ␥, and T 0 (see APPENDIX).
With four system parameters to be estimated, the degree of parameterization in Eq. 4 is high and thus may lead to parameter unidentifiability. It can be shown that one parameter can be eliminated by combining parameters into dimensionless quantities. Thus, we set
where X 0 is the reference signal of X when no drug is present and T 0 has been defined in Eq. 3. For these dimensionless variables, we obtain the system
where
are the new dimensionless parameters. For the derivation of the new system, refer to APPENDIX. After reparameterization, the number of physiological parameters has been reduced from four (a, k in , k out , and ␥) in Eq. 4 to three (A, B, and ␥) in Eq. 6, and as a result, parameter unidentifiability has been abolished. Under certain conditions, Eqs. 4 and 6 produce damped oscillations, around the equilibrium point (x , y ), defined by
The local behavior near this point can be characterized by the eigenvalues of the Jacobian matrix M, fromwhich the discriminant D can be determined (see AP-PENDIX). For Eq. 6 the discriminant becomes
When D Ͻ 0, the eigenvalues are complex, and the system of differential equations will exhibit oscillatory behavior. When D Ն 0, which is the case for a 6) following the input from C. Note that the temperature has been rescaled. The inputs used were CL, 22.8 ml/min; CL2, 13.9 ml/min, CL3, 69.2 ml/min, V1, 126 ml; V2, 2,090 ml; V3, 603 ml; kin, 0.5°C/min; TSP, 38°C; A, 0.01 min Ϫ1 ; ␥, 10; SC50, 25 ng/ml; Smax, 1; n, 1. For other definitions, see Glossary.
relatively large stimulus, the eigenvalues are real and the system of differential equations will be "overdamped." In both cases the eigenvalues have a negative real part, so that (x , y ) is asymptotically stable. The behavior of the model is depicted in a phase plot (Fig. 2C ) for low and high doses. In this picture, as the temperature starts to drop, the curves are transversed from the point (x, y) ϭ (1,1) in a clockwise fashion to the slowly moving equilibrium points (x , y ). This behavior results in temperaturetime profiles as depicted in Fig. 2D . The complex behavior of the model is further depicted in a threedimensional graph in Fig. 3 .
As the drug concentrations will be known as time progresses, substituting the expressions of Eq. 8 into Eq. 6 gives a relationship that predicts the qualitative behavior of the model at different parameter combinations. Initial estimates of the model were further obtained with the use of simulations using different parameter values, an overview of which can be found in Fig. 4 . It turns out that the model predicts the behavior as described above when S max approaches or equals 1, whereas it predicts an oscillation at all doses for S max between 0 and 1, i.e., partial agonist. This concept was implemented in Eq. 6 by defining the ranges of S max and the dependent variable y. In the model the S max value of a full agonist equals 1 and that of an antagonist equals 0. The procedure for calculating the redefined y values on the basis of the observed temperatures is represented in Eq. 10
In Eq. 10, T is the temperature at time t, T SP is the average temperature from the hour before drug administration, and T min is the average minimal temperature of the individuals receiving a high dose of the full agonists.
EXPERIMENTAL METHODS
Experiments were preformed on male Wistar rats (Broekman BV, Someren, The Netherlands) weighing 297 Ϯ 3.4 g (mean Ϯ SE, n ϭ 68) and were approved by the Leiden University Ethics Committee. The animals were housed in standard plastic cages (6 per cage before surgery and individually after surgery). They were kept in a room with a normal 12:12-h light-dark cycle (lights on at 7:00 AM and lights off at 7:00 PM) and a temperature of 21°C. During the light period, a radio was on for background noise. Acidified water and food (laboratory chow, Hope Farms, Woerden, The Netherlands) was provided ad libitum before the experiment.
Surgical Procedure
Eight days before the experiment, the rats were operated on. The animals were anesthetized with an intramuscular injection of 0.1 ml/kg Domitor (1 mg/ml medetomidine hydrochloride, Pfizer, Capelle a/d IJsel, The Netherlands) and 1 ml/kg Ketalar (50 mg/ml ketamine base, Parke-Davis, Hoofddorp, The Netherlands). Indwelling pyrogen-free cannulas were implanted into the right jugular vein (Polythene, 14 cm, 0.52-mm ID, 0.96-mm OD) for drug administration and into the left femoral artery (Polythene, 4 cm of 0.28-mm OD, 0.61-mm OD plus 20 cm of 0.58-mm ID, 0.96-mm OD) for blood sampling. Cannulas were tunneled subcutaneously to the back of the neck and exteriorized. To prevent coagulation of blood, the cannulas were filled with a 25% (wt/vol) solution of polyvinylpyrrolidone (PVP) (Brocacef, Maarssen, The Netherlands) in a 0.9% (wt/vol) pyrogen-free sodium chloride solution (NPBI, Emmer-Compascuum, The Netherlands) that contained 50 IU/ml of heparin (Leiden University Medical Center, Leiden, The Netherlands). Just before the experiment, the PVP solution was removed, and the cannulas were flushed with saline containing 20 IU/ml of heparin. The skin in the neck was stitched with normal sutures, and the skin in the groin was closed with wound clips. Furthermore, a telemetric transmitter [Physiotel implant TA10TA-F40 system, Data Sciences Internationals (DSI), St. Paul, MN], with a weight of ϳ7 g, which had been made pyrogen free with CIDEX (22 g/l glutaraldehyde, Johnson and Johnson Medical, Gargrave, Skipton, United Kingdom) for at least 2 h, was implanted into the abdominal cavity for the measurement of core body temperature. After surgery, an injection of the antibiotic ampicillin (0.6 ml/kg of a 200 mg/ml solution, AUV, Cuijk, The Netherlands) was administered to aid recovery.
Experimental Protocol
Dosage regimen. Eight days after surgery, the experiments were performed. Rats received different doses in different infusion rates of R-8-OH-DPAT or S-8-OH-DPAT. For R-8-OH-DPAT, bolus infusions of 1 mg/kg in 15 min (n ϭ 7), 3 mg/kg in 5 min (n ϭ 7), 3 mg/kg in 15 min (n ϭ 5), and 3 mg/kg in 30 min (n ϭ 6) were given. In addition, a computercontrolled infusion was administered over 6 h, by which a stable concentration of 160 ng/ml was maintained in blood (n ϭ 6). For S-8-OH-DPAT, infusions of 5 mg/kg (n ϭ 6) and 15 mg/kg (n ϭ 6) in 15 min were administered. Twenty-four rats received vehicle treatments, in which an equivalent amount of saline was infused.
For the bolus infusions, an external cannula was filled with a solution of the drug in an amount of saline calculated according to the weight of the rat, and the cannula was connected to the infusion pump (BAS beehive, Bioanalytical Systems). For the computer-controlled infusions, STAN-PUMP software (42) was used running on an IBM-compatible computer (486 processor) and connected to a Harvard 22-syringe pump (Harvard Apparatus, South Natick, MA) through an RS232 interface. The concentration was clamped using population pharmacokinetic parameters obtained in the bolus infusion experiments. All experiments started between 9:00 AM and 9:30 AM.
Blood sampling. Approximately 15-18 serial blood samples of 50 l were taken according to a fixed time schedule to determine the concentration vs. time profile of the drug. The exact amount was measured with a capillary (Servoprax, Wesel, Germany) and transferred into a glass centrifuge tube containing 400 l of purified water for hemolysis. During the experiment the samples were kept on ice. After the experiment, samples were stored at Ϫ20°C pending analysis.
Data Acquisition
Temperature measurements. To measure the body temperature of the rat, a telemetric system (Physiotel Telemetry System, DSI) was used. The transmitter measured the body temperature every 30 s for a 2-s period and signaled it to a receiver (Physiotel Receiver, model RPC-1, DSI). The receiver was connected to the computer through a BCM 100 consolidation matrix (DSI). The computer processed the data and visualized the temperature profiles [Dataquest LabPro software (DSI) running under OS/2 Warp, IBM] as it did for room temperature (C10T temperature adapter, DSI).
HPLC analysis of R-and S-8-OH-DPAT. The blood concentrations of R-and S-8-OH-DPAT were assayed by an enantioselective HPLC method as described previously (55) . Briefly, detection with the HPLC system was obtained using an electrochemical detector (DECADE, Antec Leyden, Zoeterwoude, The Netherlands) operating in DC mode at 0.63 V, at a temperature of 30°C. Chromatography was performed on a Chiralcel OD-R (Diacel Chemical Industries, Tokyo, Japan). The mobile phase was a mixture of 50 mM phosphate buffer (pH 5.5)-acetonitrile (80/20, vol/vol) and contained a total concentration of 5 mM KCl and 20 mg/l of EDTA. The analytes were extracted from blood using a liquid-liquid cleanup step and isolated on Bakerbond solid phase extraction NARC-2 columns (Baker, Phillipsburg, NJ). Calibration curves in the concentration range of 0.1-5000 ng/ml were analyzed with each run, and peak area ratios of analyte over internal standard [R-(ϩ)-7-hydroxy-2-(di-n-propylamino)tetralin (R-7-OH-DPAT)] were calculated. Using 50 l of blood, the limit of detection was 0.5 ng/ml.
Chemicals. R-8-OH-DPAT, S-8-OH-DPAT
, and R-7-OH-DPAT were purchased from Research Biochemicals International. All other chemicals used were of analytical grade (Baker, Deventer, The Netherlands).
Data Analysis
A nonlinear mixed-effects modeling approach was used to quantify both the pharmacokinetics and pharmacodynamics of R-and S-8-OH-DPAT sequentially. With this approach, the population is taken as the unit of analysis while taking into account both intraindividual variability in the model parameters, as well as interindividual residual error (39) . Modeling was performed using the nonlinear mixed-effects modeling software NONMEM developed by Sheiner and colleagues (10) (version V1.1, NONMEM Project Group, University of California, San Francisco, CA). Individual predictions were obtained in a Bayesian post hoc step. The concentration-time profiles of R-8-OH-DPAT as well as S-8-OH-DPAT were best described using a standard three-compartment pharmacokinetic model, such as implemented in NONMEM ADVAN11, TRANS4. With this routine, the pharmacokinetics were described in terms of the compartment volumes of distribution (V 1, V2, and V3), clearance (CL), and the intercompartmental clearances (CL2 and CL3). The set-point model (Eq. 6) was implemented in NONMEM using AD-VAN6. Parameterization was different from Eq. 6, where B is purely phenomenological. However, as the individual TSP Fig. 4 . Behavior of the model for different values of the model parameters. The middle line is simulated with the same pharmacokinetics as the low dose in Fig. 1 and kin ϭ 1°C/min, A ϭ 0.02 min Ϫ1 , ␥ ϭ 2, SC50 ϭ 50 ng/ml, Smax ϭ 1, and n ϭ 1. The lines beside the middle line are simulated with the values as represented in the graph, where the greatest decrease is caused by the greatest value, except for kin, where it is the lowest value.
values were known, the parameter B could be calculated from k in (see APPENDIX, Eq. A9). Therefore, the estimated physiological parameters were kin, A, and ␥. The Smax was fixed to 1 for R-8-OH-DPAT. The observed dependent variable temperature measurements were redefined as described in Eq. 10. Interindividual variability on the parameters was modeled by an exponential equation
where is the population value for parameter P, Pi is the individual value, and i is the random deviation of Pi from P. The values of i are assumed to be independently normally distributed with mean zero and variance 2 . The covariance structure of the variability parameters was assumed to be diagonal. For the pharmacokinetics, residual error was characterized by an exponential error model
where Cp,ij is the jth plasma concentration for the ith individual predicted by the model, Cm,i j is the measured concentration, and ε accounts for the residual deviance of the modelpredicted value from the observed concentration. For the pharmacodynamics, residual error was characterized by a proportional error model
where yp,ij is the jth prediction for the ith individual predicted by the model, ym,ij is the measurement, and ε accounts for the residual deviance of the model-predicted value from the observed value. The values for ε are assumed to be independently normally distributed with mean zero and variance 2 . Population pharmacokinetic values of , are estimated using the centering first-order conditional estimation method with the first-order model in NONMEM. A conditional estimation method is used because of the high degree of nonlinearity of the model and the high density of the data. The centering option gives the average estimate of each element of together with a P value that can be used to assess whether this value is sufficiently close to zero. The occurrence of an average that is significantly different from zero indicates an uncentered or a biased fit. This method was chosen to greatly decrease computing time as required with just the conditional estimation method (10, 33) . To further decrease computing time, only 1/16th of the temperature data set was used for modeling, reducing the temperature measurements from over 900 measurements per individual to ϳ60. The implication of this reduction is that there is a data point every 8 min, as opposed to every 0.5 min. This reduction did not void the integrity of the data profiles. Model selection was based on the Akaike Information Criterion (AIC; Ref.
2) and assessment of parameter estimates and correlations. Goodness-of-fit was analyzed using the objective function and various diagnostic methods as present in Xpose version 3.04 (S-plus-based model building aid; Ref. 29) .
RESULTS
The average effect-time profiles for the hypothermic response after administration of vehicle, R-8-OH-DPAT, and S-8-OH-DPAT are represented in Fig. 5 . In the control group (Fig. 5A) , rats received the amount of saline equivalent to the drug infusions used and were subjected to blood sampling. They showed no hypothermic response. The administration of R-8-OH-DPAT resulted in a maximum decrease in temperature of 4 Ϯ 0.3°C at 40 to 60 min (Fig. 5, B and D) . After an infusion of R-8-OH-DPAT of 1 mg/kg in 5 min, a complex effect vs. time profile was observed. The body temperature quickly rose after reaching its minimum; subsequently, a plateau phase was observed, after which temperature returned to baseline. For the higher doses (3 mg/kg in 5, 15, and 30 min) the plateau phase was not observed, and the body temperature returned to baseline more gradually. In the experiments in which the R-8-OH-DPAT concentration was maintained at a concentration of 160 ng/ml for 6 h, a similar plateau phase was observed, and as the infusion was turned off, the body temperature returned to baseline in a similar fashion.
On administration of S-8-OH-DPAT, a maximum decrease in body temperature of 3.2 Ϯ 0.2°C was observed within 40-60 min (Fig. 5C) . For S-8-OH-DPAT a plateau phase was observed, such as with the low dose of R-8-OH-DPAT, before returning to baseline for both infusions (5 and 15 mg/kg in 15 min).
Pharmacokinetics
During the experiments, blood samples were taken to construct individual concentration-time profiles. After the regular infusions of both R-and S-8-OH-DPAT, a distribution phase and an elimination phase were observed (Fig. 6 ). On the basis of predicted concentration curves, goodness-of-fit plots, and the AIC, the three-compartment model was selected over a twocompartment model in the pharmacokinetic analysis. The individual concentration-time profiles for R-8-OH-DPAT for both the regular infusions and the computercontrolled infusion are depicted in Fig. 6 . The population prediction for the regular infusions and for the computer-controlled infusion as well as the individually predicted curves is represented. The individual concentration-time profiles for S-8-OH-DPAT are depicted in Fig. 7 . The values of the pharmacokinetic parameter estimates are represented in Table 1 . No statistically significant correlation between the parameters was detected. Table 1 further displays the interindividual variation and the intraindividual variation for both R-and S-8-OH-DPAT.
Fitting the Set-Point Model
The effect-time profiles for R-and S-8-OH-DPAT were described by fitting the set-point model to the data. Parameters were estimated using the centering first-order conditional estimation method with the first-order model. The average values for all s were not significantly different from 0. The population parameter estimates are shown in Table 2 . Individual post hoc predictions of the parameters were found to be unbiased with respect to the different doses and infusions administered. Figure 8 depicts some typical individual and population predictions for different doses and infusions. Table 2 displays the interindividual variation and the intraindividual variation, which were both found to be reasonable for both R-and S-8-OH-DPAT. The precision with which the parameters were predicted was reasonable for both R-and S-8-OH-DPAT.
DISCUSSION

Development of the Set-Point Model
It is well established that temperature regulation in the rat takes place in the anterior hypothalamus (8, 25, 26, 47) . Furthermore, it has been recognized that serotonin plays an active role in temperature regulation and in particular in the maintenance of the body's set point (9, 28, 32, 40, 53, 54) . More recently, numerous pharmacological studies have suggested that homeostasis is achieved through an interplay between the 5-HT 1A and 5-HT 2A/C receptor systems (1, 23, 38, 40, 41) . This is further supported by the fact that both receptors are located in the hypothalamus (3, 37) amongst other regions in the brain. Administration of a 5-HT 1A -receptor agonist induces a hypothermic response both in humans and rats. This is considered to be mediated by postsynaptic 5-HT 1A receptor sites in this region (6, 20, 27, 34, 35) .
To characterize 5-HT 1A -agonist-induced hypothermia, we have developed a mathematical model that describes the hypothermic effect on the basis of the concept of a set point (8, 12, 54) and a general physiological response model (15, 19, 30) . The model developed is able to reproduce the observed complex effect vs. time profile with regard to both the delay relative to the maximal drug concentration and the plateau phase. It appears that the plateau phase originates from damped oscillations that occur around the equilibrium point on returning to baseline, when the model is not fully "pushed" into the maximal effect. When the model is fully pushed into its maximal effect, such as is the case for a relatively high dose of a full agonist, the system becomes overdamped, thereby losing its oscillatory behavior. Hence, the observed plateau phase is an intrinsic part of the regulatory mechanism related to the oscillatory behavior found in many regulatory systems (22, 31) .
Because the model as represented by Eq. 4 is overparameterized, the model was simplified by introducing dimensionless quantities. Such operation does not change the behavior of the model but merely reduces the parameters that are correlated. One major drawback of this approach is, however, that the parameters become difficult to interpret. On the other hand, a major advantage is that it becomes possible to estimate the parameters with a higher degree of certainty. To fully utilize the properties of the model, the temperature data were rescaled as well. This was done under the assumption that R-8-OH-DPAT is the fullest agonist and that the maximal temperature decrease observed was indeed the maximum. Despite the fact that it is well known that temperature is regulated within a narrow range, it Intraindividual coefficient of variation (CV) was 25.7% for R-( ϩ )-8-hydroxy-2-(di-n-propylamino)tetralin (R-8-OH-DPAT) parameter values and 15.7% for S-( Ϫ )-8-hydroxy-2-(di-n-propylamino)tetralin (S-8-OH-DPAT) parameter values. 95% CI, 95% confidence interval over the precision of the estimated parameter; CL, clearance of drug from body; CL2 and CL3, intercompartmental clearance; V1, volume of distribution of central compartment; V2 and V3, volume of distribution of peripheral compartments. has been shown that when the body temperature does drop below approximately 4-4.5°C below its homeostatic temperature, either very long recovery times are observed (Ͼ10 h) or the animals die. Examples of such experiments include administration of the adenosine agonist 5Ј-(N-ethylcarboxamido)adenosine and high but nonlethal doses of pentobarbital or clozapine (unpublished results). It is therefore reasonable to assume that the absolute drop as observed with R-8-OH-DPAT is the absolute maximum for the range in which the set-point system operates.
Because it is known from both in vitro and in vivo data that R-and S-8-OH-DPAT are, respectively, full and partial agonists for the hypothalamic 5-HT 1A receptor (14) and behave as such for the hypothermic response (24), we were interested in estimating the intrinsic activity and potency of these compounds on the basis of our model. Despite the fact that it has been suggested that the hypothermic effect of S-8-OH-DPAT is mediated via the dopamine D 2 receptor (52), we have not been able to reproduce this result and were able to block the S-8-OH-DPAT-mediated hypothermic effect using the selective 5-HT 1A receptor antagonist WAY-100,635 (results not shown). Furthermore, we could not block the S-8-OH-DPATmediated response using the a-selective dopamine receptor antagonist haloperidol (results not shown). Finally, we were unable to block an effective dose of the selective dopamine D 3 receptor agonist R-7-OH-DPAT, which does induce a hypothermic response in our studies (results not shown). These findings show that the observed hypothermic response after S-8-OH-DPAT is mediated exclusively through the 5-HT 1A receptor.
Fitting the Set-Point Model
To construct a concentration-effect relationship for R-and S-8-OH-DPAT, it was necessary to study the pharmacokinetics of both compounds. Both concentration-time profiles were estimated using a population-based three-compartment pharmacokinetic model. The pharmacokinetics of R-8-OH-DPAT could be estimated with a high degree of precision, whereas the precision of the estimation of S-8-OH-DPAT pharmacokinetics was somewhat poorer. The reason for this may be the large half-life of S-8-OH-DPAT (ϳ15 h) relative to the duration of the study. In this respect, it is interesting to note that the difference in pharmacokinetics between R-8-OH-DPAT (half-life of 86 min) and S-8-OH-DPAT indicate a highly stereoselective metabolism. In the analysis of the effect on body temperature, the individual post hoc pharmacokinetic parameters were used for interpolation to estimate the drug concentration at every measurement of body temperature. The proposed physiological PK-PD model was able to describe the plateau phase observed for the low dose of R-8-OH-DPAT and not for the high dose in a single analysis. Additionally, the computer-controlled infusions in which an R-8-OH-DPAT concentration of 160 ng/ml is maintained in blood for 6 h follow a behavior that is also fitted by the model. Furthermore, it predicts a plateau phase for both doses of the partial agonist S-8-OH-DPAT. Overall, the individual predictions describe the shape of the observed responses well, and the parameters obtained are independent of dose or infusion. The parameters obtained show reasonable interindividual variances and intraindividual variance. Despite the fact that a number of parameters associated with the physiological part of the model are different between R-and S-8-OH-DPAT, they are within a physiological range of each other, whereas the S max and SC 50 are markedly different.
General Conclusions
The parameters obtained from describing both the pharmacokinetics and the pharmacodynamics of both R-and S-8-OH-DPAT clearly indicate a stereoselective metabolism, a difference in potency, and a marked difference in intrinsic activity (Fig. 9) for the hypothermic effect. These findings comply with in vitro data, where affinity for both compounds is very similar (5, 36) and an efficacy of ϳ50% is found for S-8-OH-DPAT in functional assays (13) . The model that was developed incorporates the set-point hypothesis in temperature regulation to explain the hypothermic response to the 5-HT 1A receptor in terms of its oscillatory behavior.
Perspectives
This study shows that it is possible to predict the time course of drug effects in vivo in situations where complex homeostatic control mechanisms are operative. As such, it forms the basis for the development of an entirely new class of PK-PD models. These models are important for the development of new drugs and the application of such drugs in clinical practice. For example, on the basis of this kind of model, it becomes possible to predict whether withdrawal symptoms will occur on cessation of (chronic) drug treatment. Hence, these models may provide a scientific basis either for the selection of alternate drug candidates or the design of dosing regimens that show less pronounced withdrawal phenomena. It is further anticipated that such models will provide a basis for PK-PD modeling with disease progression. 
